David Sidransky
Director @ Advaxis
David Sidransky is a Series B investor at Advaxis focused on Health Care and Biotechnology. Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Since 1994, Dr. Sidransky has been the Director of the Head and Neck Cancer Research Division and Professor of Oncology,Otolaryngology, Genetics, and Pathology at Johns Hopkins University School of Medicine. He has served as Chairman of the Board of Directors of Champions Oncology since October 2007 and was, until the merger with Eli Lilly, a director and Vice-Chairman of ImClone Systems, Inc. He is the Chairman of Tamir Biotechnology and serves on the Board of Directors of Rosetta Genomics, Immune Pharmaceuticals, and Celsus. He is serving and has served on scientific advisory boards of MedImmune, Roche, Amgen, and Veridex, LLC (a Johnson & Johnson diagnostic company), among others. Dr. Sidransky served as Director (2005-2008) of the American Association for Cancer Research (AACR).
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries David Sidransky invests in
Stages David Sidransky invests in
Countries David Sidransky invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (67%)
- Biotechnology 2 (67%)
- Pharmaceutical 2 (67%)
- Therapeutics 1 (33%)
Stage
- Series B 1 (33%)
- Series C 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
BioSight
|
BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantlyminimizing the systemic toxicity associated with conventional chemotherapy treatments. | $27M / Series C / Dec 02, 2020 | |
|
BioSight
|
BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantlyminimizing the systemic toxicity associated with conventional chemotherapy treatments. | $19M / Series C / Mar 11, 2020 | |
Biond Biologics
|
Biond Biologics is a discovery and development company in the prosperous and evolving field of cancer immunotherapy and autoimmune disorders. Biond aims to translate high quality science into breakthrough therapies that will address unmet medical needs while focusing on innovative drugs. Biond is an Israeli company located at Galilee region,combining excellent science and out of the box innovation. | $17M / Series B / Jan 08, 2019 |
Co-Investors
About Advaxis
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immuneresponse all human beings have to the bacterium to the cancer itself.ADXS-HPV is being evaluated in four clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study), head and neck cancer (CRUK study), and anal cancer (BrUOG). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence.
Advaxis Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
David Sidransky
Director
|
|||
Andres Gutierrez
Executive Vice President & Chief Medical Officer
|
|||
Chris French
Vice President and Executive Director, Medical Affairs
|
|||
Chris L. French
Vice President and Executive Director, Medical Affairs
|
|||
Igor Gitelman
Vice President Finance
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does David Sidransky invest in?
David Sidransky invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series B and Series C stage. Most of the 3 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact David Sidransky?
Public channels for David Sidransky include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did David Sidransky last invest?
The most recent investment recorded for David Sidransky closed in Dec 2020. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
